Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts

被引：0

作者：

Sifat Sharmin

Mathilde Lefort

Johanna Balslev Andersen

Emmanuelle Leray

Dana Horakova

Eva Kubala Havrdova

Raed Alroughani

Guillermo Izquierdo

Serkan Ozakbas

Francesco Patti

Marco Onofrj

Alessandra Lugaresi

Murat Terzi

Pierre Grammond

Francois Grand’Maison

Bassem Yamout

Alexandre Prat

Marc Girard

Pierre Duquette

Cavit Boz

Maria Trojano

Pamela McCombe

Mark Slee

Jeannette Lechner-Scott

Recai Turkoglu

Patrizia Sola

Diana Ferraro

Franco Granella

Julie Prevost

Davide Maimone

Olga Skibina

Katherine Buzzard

Anneke Van der Walt

Bart Van Wijmeersch

Tunde Csepany

Daniele Spitaleri

Steve Vucic

Romain Casey

Marc Debouverie

Gilles Edan

Jonathan Ciron

Aurélie Ruet

Jérôme De Sèze

Elisabeth Maillart

Hélène Zephir

Pierre Labauge

Gilles Defer

Christine Lebrun-Frénay

Thibault Moreau

Eric Berger

机构：

[1] University of Melbourne,CORe, Department of Medicine

[2] Rennes University,The Danish Multiple Sclerosis Registry, Department of Neurology

[3] EHESP,Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine

[4] REPERES,Division of Neurology, Department of Medicine

[5] EA,Department of Medical and Surgical Sciences and Advanced Technologies

[6] Univ Rennes,Multiple Sclerosis Center

[7] CHU Rennes,Department of Neuroscience, Imaging, and Clinical Sciences

[8] Inserm,Dipartimento di Scienze Biomediche e Neuromotorie

[9] CIC 1414 (Centre d’Investigation Clinique de Rennes),Medical Faculty

[10] University of Copenhagen,Nehme and Therese Tohme Multiple Sclerosis Center

[11] Charles University in Prague and General University Hospital,Department of Basic Medical Sciences, Neuroscience and Sense Organs

[12] Amiri Hospital,College of Medicine and Public Health

[13] Hospital Universitario Virgen Macarena,School of Medicine and Public Health

[14] Dokuz Eylul University,Department of Neurology, John Hunter Hospital

[15] GF Ingrassia,Department of Neuroscience

[16] University of Catania,Department of Medicine and Surgery

[17] University G. d’Annunzio,Department of Emergency and General Medicine

[18] IRCCS Istituto delle Scienze Neurologiche di Bologna,Neurology Unit

[19] Università di Bologna,Department of Neuroscience

[20] 19 Mayis University,Department of Neurology

[21] CISSS Chaudière-Appalache,Central Clinical School

[22] Neuro Rive-Sud,Department of Neurology, Faculty of Medicine

[23] American University of Beirut Medical Center,Neurophysiology Department

[24] CHUM MS Center and Universite de Montreal,Service de neurologie, sclérose en plaques, pathologies de la myéline et neuro

[25] KTU Medical Faculty Farabi Hospital,inflammation, Hôpital Neurologique Pierre Wertheimer

[26] University of Bari,Department of Neurology

[27] University of Queensland,Department of Neurology

[28] Royal Brisbane and Women’s Hospital,Neurocentre Magendie

[29] Flinders University,Department of Neurology

[30] University Newcastle,Département de neurologie

[31] Hunter New England Health,MS Unit

[32] Haydarpasa Numune Training and Research Hospital,Department of Neurology, CHU de Caen, MS Expert Centre

[33] Azienda Ospedaliera Universitaria,Department of Neurology

[34] University of Parma,Department of Neurology

[35] Parma University Hospital,Department of Neurology

[36] CSSS Saint-Jérôme,Department of Neurology

[37] Garibaldi Hospital,Department of Neurology

[38] Monash University,Department of Neurology

[39] The Alfred Hospital,Department of Neurology

[40] Monash University,Department of Neurology

[41] Rehabilitation and MS-Centre Overpelt and Hasselt University,Department of Neurology

[42] University of Debrecen,Department of Neurology

[43] Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati Avellino,Department of Neurology

[44] Westmead Hospital,Department of Neurology

[45] Université de Lyon,CRC SEP and Department of Neurology

[46] Université,Department of Neurology

[47] Hospices Civils de Lyon,Department of Neurology

[48] Observatoire Français de la Sclérose en Plaques,Department of Neurology

[49] Centre de Recherche en Neurosciences de Lyon,Department of Neurology

[50] INSERM 1028 et CNRS UMR 5292,Department of Neurology

来源：

CNS Drugs | 2021年 / 35卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1217 / 1232

页数：15

共 50 条

[31] Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies
Baroncini, Damiano
Ghezzi, Angelo
Annovazzi, Pietro O.
Colombo, Bruno
Martinelli, Vittorio
Minonzio, Giorgio
Moiola, Lucia
Rodegher, Mariaemma
Zaffaroni, Mauro
Comi, Giancarlo
MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (10) : 1315 - 1326
[32] COST ANALYSIS OF GLATIRAMER ACETATE VERSUS FINGOLIMOD FOR THE TREATMENT OF PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SPAIN
Sanchez-de la Rosa, R.
Sabater, E.
Casado, M. A.
VALUE IN HEALTH, 2012, 15 (07) : A551 - A551
[33] The efficacy of natalizumab versus fingolimod for patients with relapsing-remitting multiple sclerosis: a systematic review and meta-analysis of randomized and observational study data
Tsivgoulis, G.
Katsanos, A. H.
Mavridis, D.
Grigoriadis, N.
Dardiotis, E.
Heliopoulos, I.
Papathanasopoulos, P.
Kilidireas, C.
Hadjigeorgiou, G. M.
Voumvourakis, K.
MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 597 - 597
[34] Effects of fingolimod in relapsing-remitting multiple sclerosis Comment
Sorensen, Per Soelberg
LANCET NEUROLOGY, 2014, 13 (06): : 526 - 527
[35] ORAL FINGOLIMOD FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS
Vosiliou, S.
DRUGS OF TODAY, 2010, 46 (05) : 315 - 325
[36] Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study
Butzkueven, Helmut
Licata, Stephanie
Jeffery, Douglas
Arnold, Douglas L.
Filippi, Massimo
Geurts, Jeroen J. G.
Santra, Sourav
Campbell, Nolan
Ho, Pei-Ran
BMJ OPEN, 2020, 10 (10):
[37] Efficacy of fingolimod in patients with highly active relapsing-remitting multiple sclerosis
Derfuss, T.
Bergvall, N. K.
Sfikas, N.
Tomic, D. L.
CURRENT MEDICAL RESEARCH AND OPINION, 2015, 31 (09) : 1687 - 1691
[38] Comparison of the effectiveness of ocrelizumab vs interferons, fingolimod and natalizumab on relapses in relapsing-remitting multiple sclerosis
Roos, I.
Sharmin, S.
Ozakbas, S.
Horakova, D.
Havrdova, E. K.
Boz, C.
Alroughani, R.
Patti, F.
Terzi, M.
Lechner-Scott, J.
Izquierdo, G.
Eichau, S.
Grammond, P.
Buzzard, K.
Skibina, O.
Prat, A.
Girard, M.
Duquette, P.
Soysal, A.
Grand'Maison, F.
Kuhle, J.
van der Walt, A.
Butzkueven, H.
Turkoglu, R.
Butler, E.
Laureys, G.
van Hijfte, L.
Shaygannejad, V.
Yamout, B.
Khoury, S.
Prevost, J.
Sidhom, Y.
Gouider, R.
Cartechini, E.
Sanchez-Menoyo, J. L.
Sa, M. Jose
Macdonell, R.
van Pesch, V.
Ramo-Tello, C.
McCombe, P.
Willekens, B.
Spitaleri, D.
Ampapa, R.
Al-Asmi, A.
Slee, M.
Besora, S.
Malpas, C.
Kalincik, T.
MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 778 - 780
[39] Safety and Efficacy of Fingolimod in Iranian Patients with Relapsing-remitting Multiple Sclerosis
Yavari, Fatemeh
Oliazadeh, Pardis
Radfar, Meisam
Foroughipour, Mohsen
Nikkhah, Karim
Bakavoli, Alireza Heidari
Saeidi, Morteza
BASIC AND CLINICAL NEUROSCIENCE, 2021, 12 (02) : 233 - 242
[40] Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing-Remitting Multiple Sclerosis
Grahl, S.
Bussas, M.
Wiestler, B.
Eichinger, P.
Gaser, C.
Kirschke, J.
Zimmer, C.
Berthele, A.
Hemmer, B.
Muehlau, M.
NEUROTHERAPEUTICS, 2021, 18 (04) : 2589 - 2597

← 1 2 3 4 5 →